-
International Myeloma Working Group International Myeloma Working group consensus statement regarding the current status of allogeneic stem cell transplantation for Multiple myeloma Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel JF, Pérez-Simon JA, Kröger N, Moreau P, Gahrton G, Gasparetto C, Giralt S, Bensinger W. Journal of Clinical Oncology 28(29):4521-30. FI: 17.793 (Q1) Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide. Introduction and overview San Miguel JF. Blood Reviews 24 Suppl 1:S1-3. FI: 7.185 (Q1) Management of treatment-related adverse events in patients with multiple myeloma Mateos MV. Cancer Treatment Reviews 36 Suppl 2:S24-32. FI: 5.295 (Q1) Monoclonal gammopathy of undetermined significance: a consensus statement Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA. British Journal of Haematology 150(1):28-38. FI: 4.597 (Q1) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMW consensus perspectives risk factors for progression and guidelines for monitoring and management Kyle RA, Durie BG, Rajkumar SV, Landgren O, Bladé J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel JF, Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumgo A, Richardson PG, Barlogie B, Vescio R, Turesson I, Westin J, Boccadoro M., International Myeloma Working Group. Leukemia 24(6):1121-7. FI: 8.296 (Q1) Novel treatment regimens for Waldenström's macroglobulinemia García-Sanz R, Ocio EM. Expert Review of Hematology 3(3):339-50. FI: 2.493 (Q3) Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, de la Rubia J, Lahuerta JJ, García-Sanz R, Extremera S, Szyldergemajn S, Corrado C, Singer H, Mitsiades CS, Anderson KC, Bladé J, San Miguel JF. Clinical Cancer Research 16(12):3260-9. FI: 6.747 (Q1) Primary Health Care Group of Salamanca for the Study of MBL. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic Perez-Andres M, Paíva B, Nieto WG, Caraux A, Schmitz A, Almeida J, Vogt RF Jr, Marti GE, Rawstron AC, Van Zelm MC, Van Dongen JJ, Johnsen HE, Klein B, Orfao A. Cytometry Part B Clinical Cytometry 78 Suppl 1:S47-60. FI: 1.727 (Q2) P53 deletion may drive the clinical evolution and treatment response in multiple myeloma López Anglada L, Gutiérrez NC, García JL, Mateos MV, Flores T, San Miguel JF. European Journal of Haematology 84(4):359-61. FI: 2.345 (Q3) Renal Impairment in Patients with Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Rajkumar SV, Durie BG, San Miguel JF. Journal of Clinical Oncology 28(33):4976-84. FI: 17.793 (Q1)
|
